South Carolina Life Sciences Industry Honors Commerce Secretary Hitt, Abbott's Tom Strange, Nephron Pharmaceuticals for Leadership, Contributions to IndustrySC Commerce's Bobby Hitt, Abbott's Tom Strange, Nephron saluted by SCBIO see more
Nearly 350 industry leaders on hand to salute inaugural honorees for commitment to advancing South Carolina’s booming life sciences industry
NOVEMBER 2, 2018 – To resounding applause from a record gathering from 4 countries, 22 states and virtually every county in South Carolina, life sciences leaders saluted three leaders – two individuals and one organization – for profound positive impact and exceptional contributions to the advancement of South Carolina’s $11.4 billion life sciences industry.
South Carolina Secretary of Commerce Robert M. “Bobby” Hitt III was presented with the inaugural South Carolina Life Sciences Hall of Fame Award for his personal championing of the life sciences industry, which today has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products. SC Commerce is a Founding Partner and strategic supporter of SCBIO, and has been highly instrumental in helping the rapid growth of life sciences in the Palmetto State.
Mr. Hitt has served as South Carolina Secretary of Commerce since January 2011. Promoting a team-first approach to economic development, Hitt has positioned the S.C. Department of Commerce and its many partners and allies for industry recruitment success. Since 2011, Team South Carolina has recruited more than $35 billion in capital investment and approximately 125,000 new jobs to the state. This year alone, multiple world-class companies have made significant investments in South Carolina, including BMW, Samsung and Volvo Cars. Before his time as Secretary of Commerce, Hitt served as manager of Corporate Affairs at the BMW Manufacturing Company in Spartanburg County after 17 years as managing editor of The State and Columbia Record newspapers.
Presented with the inaugural South Carolina Life Sciences Pinnacle Award for Individual Contribution to the industry was Tom Strange, Senior Director of Research & Development for Abbott Labs in Liberty, South Carolina. With an extensive background in materials science, Mr. Strange holds 48 patents and has authored numerous papers covering all aspects of capacitor development. He began his illustrious career with Philips Components in 1979 leading research activity involving development of capacitors that made thoracic implantable cardioverter defibrillators possible. Today, with over 20 years at St Jude Medical/Abbott, his team continues to define state of the art in implantable medical devices for pacing and arrhythmia correction, neuromodulation and battery performance.
Honored for his exceptional industry-related contributions and profound impact on the state, its citizens and the life sciences industry, Mr. Strange led efforts to establish SC Launch!, the public/private initiative with the SC legislature to fund start-up activities in SC under SCRA, and helped to launch SCBIO as an affiliate of the national BIO organization. He holds numerous honors and awards, and earned undergraduate and graduate degrees in Physics from the University of South Carolina.
Presented with the inaugural South Carolina Life Sciences Pinnacle Award for Organizational Contribution to the industry was Nephron Pharmaceuticals of West Columbia, represented by owners Lou and Bill Kennedy. A Vision Partner of SCBIO, CEO Lou Kennedy joined Nephron Pharmaceuticals in 2001, and was named President/CEO in 2007. She led the creation of a state of the art manufacturing facility in West Columbia in 2014, and oversaw development of a national sales force which helped Nephron grow by 300% and increased shipped product to over one billion doses annually.
Honored for Nephron’s economic, innovation, social and quality of life impact in the state, the Kennedy’s helped establish the Kennedy Pharmacy Innovation Center in conjunction with the USC School of Pharmacy. Ms. Kennedy serves on or chairs numerous boards including those of SCBIO, the SC Chamber of Commerce, the National Bank of South Carolina, and the South Carolina Manufacturers Alliance.
The three honorees joined BIO global CEO Jim Greenwood and more than 50 additional national speakers at SCBIO 2018 – the annual conference which brought top leaders and executives from life sciences organizations across the state and nation to Charleston, South Carolina October 23-25.
Included among attendees were scores of top industry chief executives, leaders in government and higher education, biotechnology and pharma executives, clinicians and researchers, and industry supporters from across America including DePuy Synthes Global Orthopedic Leader I.V. Hall, J.P. Morgan Executive Director of Healthcare Investment Banking Bell Zhong, MUSC President David Cole, USC President Harris Pastides, Siemens Healthineers North Americas President Dave Pacitti, and numerous others.
SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state. The industry has an $11.4 billion economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products.
“The life sciences industry is a major driver of South Carolina’s economy, and these noted honorees and this conference is testament to the industry’s growing impact, reach and rapidly rising economic significance in our state and region,” noted SCBIO President and CEO Sam Konduros. “We’re pleased to honor them for their many contributions, and salute them for the advances they have facilitated for this industry.”
As the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – SCBIO members include hundreds of academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world.
For additional information on SCBIO, visit www.SCBIO.org.
Greenwood, South Carolina's globally recognized genetics center is further investing... see more
Greenwood Genetic Center has invested more than $1.75 million in laboratory equipment and a new on-site aquaculture facility that the organization says is the largest zebrafish facility in the state.
The new equipment includes a NovaSeq DNA sequencing system and a confocal microscopy system. The Illumina NovaSeq 6000 System offers high-throughput sequencing across a broad range of applications. The NovaSeq also meets the research needs of both the center and the Clemson Center for Human Genetics. Read the full news release here.
A Columbia, SC-based biotech firm has introduced a new INTip solution with a proprietry design... see more
Columbia, SC – DPX Technologies announces a new INTip solution that utilizes a proprietary design for micro-elution dispersive solid phase extraction. DPX INTip solutions are designed to simplify sample preparation methods, and the μElution dSPE tip provides an automated solution for optimal sensitivity.
“The μElution dSPE tips were developed as an addition to the dSPE product line, that give our customers the ability to reduce elution volumes and increase sensitivity for downstream analysis,” said William E. Brewer, Ph.D., Founder and CEO of DPX Technologies. “DPX micro-elution methods eliminate solvent evaporation and reduce the challenges for sample preparation of high throughput, high sensitivity assays.”
Humimic is opening doors to a world of medical research from right here in South Carolina see more
Accompanied by a contingent of life sciences leaders from SCBIO, the South Carolina Department of Commerce, Upstate Alliance, the Charleston Regional Development Alliance and others, South Carolina is making its presence felt at Arab Health 2019 -- the global medical and life sciences conference held annually in Dubai. And Greenville's own Humimic Medical is making its own presence felt as well.
Imagine a gelatin solution that mimics soft human tissue. One that doesn’t require refrigeration, and that opens doors to a world of medical industry research and training without the obstacles that come with cadavers.
The product exists, developed eight years ago by Joel Edwards in his Arkansas basement. It was sparked by an idea, and initially sold to defense companies for testing under the name Clear Ballistics.
In recent years, physicians and medical researchers took notice, prompting the spinoff of a company called Humimic Medical.
Moterum selected to present at prestigious medtech conference in Chicago, IL see more
Southeastern medtech company develops mobility solutions for patients suffering from strokes, neural traumas; forum convenes investors seeking leading-edge advances in health and life sciences
GREENVILLE, S.C. – July 11, 2018 – Moterum Technologies Inc., a South Carolina-based mobility and gait rehabilitation development company, has been selected to present at the prestigious Cavendish BioHealth Impact Forum July 17-18, 2018 in Chicago, Illinois. The Forum provides an environment for organizations and investors to further their strategic social impact investing, grant-giving, and philanthropy programs in support of health and life sciences advances.
Co-hosted by Cavendish Global, the Shirley Ryan AbilityLab, and MATTER, the Forum showcases presentations and panel discussions by leading research institutions, private-sector companies, nonprofit organizations, and foundations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. Cavendish BioHealth Impact Forums are hosted by leading institutions around the United States and take place several times each year.
Moterum Technologies is one of 10 featured organizations invited to present their solutions at the Chicago Conference. An innovative medical technology development company, Moterum’s focus is designed to help resolve mobility and gait problems for patients suffering a neural trauma, such as a stroke. Its lead product is a fully connected, smart device that teaches stroke patients how to re-learn walking in their own home.
“We are honored to be selected to present at the 2018 Chicago Forum, and value the recognition it will provide of our innovative approach to helping stroke survivors walk independently and without a limp or asymmetry,” said David Huizenga, CEO of Moterum Technologies. “Our device can be used at home and is fully connected and positioned for telehealth systems, making it a viable solution for developed and developing health systems alike. We welcome the chance to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to improving the health and lives of people around the world.”
The Cavendish community consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish BioHealth Impact Forum provides impact investors with a curated, peer-to-peer knowledge expansion and relationship building environment, and seeks to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.
“With the help of our expert team, Selection Committee and advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence,” said J. Michael Moffat, Chairman of Cavendish Global. “The quality and originality of Moterum Technologies’ research and scientific insights in treating gait problems of stroke survivors positions them to make a major contribution to global health by helping stroke survivors retake an independent position in society.”
For further information on Moterum Technologies, visit www.moterum.com.
About Moterum Technologies Inc.
Moterum Technologies is an innovative medical technology development company that focuses on solving mobility and gait problems for patients suffering a neural trauma, such as a stroke. Its lead product is a fully connected, smart device that teaches stroke patients to relearn how to walk in their own home.
Personalized approaches to treating autism spectrum disorder advance... see more
The Greenwood Genetic Center and Swiss biotechnology innovator, Stalicla, have signed a research agreement to collaborate on personalized approaches to treating autism spectrum disorder, or ASD. Stalicla has developed an algorithm platform based on big data to bring precision medicine to subtypes of autism spectrum disorder patients, according to a news release.
“Over the past 10 years, evidence has accumulated pointing toward alterations in molecular pathways that lead to abnormal cell functioning in ASD,” said Lynn Durham, CEO of Geneva-based Stalicla, in the release. “At Stalicla, we are looking to bring disease-modifying personalized medicine to patients with ASD, one subgroup after the other.”
Avara Pharmaceutical Services finalizes acquisition of GSK Consumer Healthcare facility in South CarolinaAvara Pharmaceutical Services has completed a South Carolina acquisition from GSK see more
Avara Pharmaceutical Services, a world-class contract development and manufacturing organization (CDMO), announced that the acquisition of the GlaxoSmithKline (GSK) consumer healthcare manufacturing facility in Aiken, South Carolina (USA) is complete. Read on for full details...